Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cell Proliferation
100%
Immunogenicity
100%
Tumor Immunity
100%
Histone Deacetylase 6 (HDAC6)
100%
Anti-melanoma
100%
Tumor Growth
66%
Apoptosis Induction
66%
Melanoma Cells
66%
Further Development
33%
In Cancer
33%
Histone Deacetylase Inhibitor (HDACi)
33%
Cancer Treatment
33%
Metastatic Melanoma
33%
CD4+
33%
Cancer Cells
33%
Epigenetic Modifiers
33%
Tumor Antigen
33%
Operative
33%
Potential Therapeutics
33%
Pharmacological Inhibitors
33%
CD8+
33%
Recent Advances
33%
MHC Class I
33%
Overall Survival
33%
Cell Cycle Arrest
33%
In Vitro Proliferation
33%
Anti-melanogenic Activity
33%
Survivability
33%
Apoptotic Cells
33%
Mutational Status
33%
Median Survival
33%
Abrogation
33%
Potential Improvement
33%
G1 Arrest
33%
Melanocytic Tumor
33%
HDAC6 Inhibitor
33%
Biochemistry, Genetics and Molecular Biology
Cell Proliferation
100%
Immunogenicity
100%
Histone Deacetylase
100%
HDAC6
66%
Tumor Progression
66%
Programmed Cell Death
66%
Genetics
33%
MHC Class I
33%
Cancer Cell
33%
Upregulation
33%
Overall Survival
33%
Cell Cycle Arrest
33%
G1/S Transition
33%
Cell Cycle Checkpoint
33%
CD4
33%
CD8
33%
Tumor Antigen
33%
Immunology and Microbiology
Immunogenicity
100%
Cell Proliferation
100%
Histone
100%
Programmed Cell Death
66%
G1 Phase Cell Cycle Checkpoint
33%
CD4
33%
Cancer Cell
33%
Melanoma Cell
33%
CD8
33%
Upregulation
33%
Overall Survival
33%
Cell Cycle Arrest
33%
MHC Class I
33%
Melanoma Cell Line
33%
Tumor Antigen
33%
Cell Cycle Checkpoint
33%
In Vitro
33%
Pharmacology, Toxicology and Pharmaceutical Science
Histone Deacetylase 6
100%
Melanoma
100%
Immunogenicity
50%
Malignant Neoplasm
33%
Tumor Growth
33%
Histone Deacetylase Inhibitor
16%
Metastatic Melanoma
16%
CD8 Antigen
16%
Overall Survival
16%
Tumor Antigen
16%